News & Updates
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its founder Andrew Buckler will present findings from two separate studies at the virtual Society of Cardiovascular Computed Tomography (SCCT) 16th Annual Scientific Meeting.…
Read More
Excerpt from the Press Release: MARLBOROUGH, Mass., July 19, 2021 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that the Phenoptics™ mIF solution was used in a multi-site study to demonstrate and validate an automated end-to-end workflow that characterizes PD-1/PD-L1 immune checkpoint signaling in tumor tissue samples. The paper…
Read More
Excerpt from the Press Release: MALVERN, Pa., July 15, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it had initiated a rolling submission to Health Canada for COVAXIN™, the company’s candidate…
Read More
Excerpt from the Press Release: CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Qualigen’s…
Read More
Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing. Furthermore, IMM-BCP-01 showed in-vitro activity…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., July 15, 2021 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced the publication of preclinical data in the peer-reviewed journal Cancer Immunology, Immunotherapy, for…
Read More Excerpt from the Article: One of the most common cancers among men in the United States, prostate cancer is second in prevalence only to skin cancer. Approximately 12.5 percent of men will be diagnosed with prostate cancer at some point during their lifetimes. Put another way, out of every 100 American men, approximately 13 will get prostate cancer during…
Read More
Excerpt from the Press Release: BOSTON, July 15, 2021 /PRNewswire/ — COTA, Inc., an oncology real-world data and analytics company, announced a new research partnership with MedStar Health. COTA will support MedStar Health in its use of real-world data to accelerate scientific discovery and improve care for cancer patients. MedStar Health is the largest healthcare provider in the Maryland and Washington, D.C.,…
Read More
Excerpt from the Article: In men who have prostate cancer, pairing active surveillance with prostate MRI is a more cost-effective approach to treatment over time than relying on active surveillance, repeated biopsy and prostate-specific antigen (PSA) tests. These findings, published July 14 in Radiology, come on the heels of additional research that indicates prostate MRI can…
Read More
Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–Two new studies propose the first model for diagnosing, indexing and monitoring Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID. The findings also provide a framework for understanding the cause of, and potential treatment for, long COVID. Long COVID is believed…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?